BJO

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 17 April 2008. doi:10.1136/bjo.2007.131771
British Journal of Ophthalmology 2008;92:795-799
Copyright © 2008 by the BMJ Publishing Group Ltd.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
bjo.2007.131771v1
92/6/795    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ockrim, Z K
Right arrow Articles by Hykin, P
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ockrim, Z K
Right arrow Articles by Hykin, P
Topic Collections
Right arrowRelevant Article

ORIGINAL ARTICLES

Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema

Z K Ockrim1, S Sivaprasad2, S Falk2, S Roghani2, C Bunce2, Z Gregor2, P Hykin2

1 Giffnock, Glasgow, UK
2 Moorfields Eye Hospital, London, UK

Correspondence to:
Ms Z K Ockrim, Royal Alexander Hospital, Corsebar Road, Paisley PA2 9PN, UK; zoe_ockrim{at}hotmail.com

Aim: To determine if repeated intravitreal triamcinolone improves best corrected visual acuity at 1 year compared with conventional laser therapy for persistent diabetic macular oedema.

Methods: 88 eyes with persistent clinically significant macular oedema, after at least one prior laser photocoagulation, were included in this prospective randomised controlled trial. 43 patients were randomised to 4 mg of intravitreal triamcinolone (TA) and 45 to laser photocoagulation. The primary endpoint was the proportion of patients who improved by 15 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters at 12 months in TA versus laser groups. Secondary endpoints were the change in mean best corrected visual acuity, difference in macular thickness and macular volume and adverse event reporting in particular elevated intraocular pressure at 12 months.

Results: Improvement in >=15 ETDRS letters occurred in two of 42 patients in the TA group (4.8%) and in five of 41 (12.2%) patients in the laser group (p = 0.265). At baseline, the mean ETDRS scores at baseline were 54.4 letters in the TA group and 53.0 letters in the laser group. At 12 months, these were 54.5 and 54.6, respectively. Optical coherence tomography showed a reduction in central macular thickness of 82.0 µm with TA and 62.3 µm with laser at 12 months. There was one case of sterile endophthalmitis. 22 out of 43 patients in the triamcinolone group required ocular antihypertensives.

Conclusion: This study did not show a benefit from intravitreal triamcinolone over conventional laser therapy for patients with chronic diabetic macular oedema


Competing interests: None.

Ethics approval: This prospective randomised trial was conducted in accordance with the ethical standards of the Declaration of Helsinki and was approved by the local Research and Ethics Committees at Moorfields Eye Hospital.

Patient consent: Written informed consent was obtained from all patients before details of medical and ophthalmic examinations were recorded.


Relevant Article

At a glance
Harminder S Dua and Arun D Singh
Br. J. Ophthalmol. 2008 92: 727. [Extract] [Full Text] [PDF]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 by the BMJ Publishing Group Ltd.